Sublingual immunotherapy for aeroallergens: Status in the United States

Allergy and Asthma Proceedings

Volumn 35, Issue 1, 2014, Pages 34-42

  Cox, Linda ^a  

^a UNIVERSITY OF NORTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AEROALLERGEN; ALLERGEN; ALT A 1 ALLERGEN; AMB A 1 ALLERGEN; ANTIHISTAMINIC AGENT; BET V 1 ALN G 1 COR A 1 ALLERGEN; CAT HAIR ALLERGEN; COCKROACH ALLERGEN; DER F 1 ALLERGEN; DER P 1 ALLERGEN; DOG ALLERGEN; FEL D 1 ALLERGEN; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; PARIETARIA ALLERGEN; PHL P 1 ALLERGEN; PHL P 5 ALLERGEN; PLACEBO; POLLEN ANTIGEN; POLLEN EXTRACT; RAGWEED ANTIGEN; STEROID; UNCLASSIFIED DRUG;

ABDOMINAL DISEASE; ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; ANXIETY; APHTHOUS ULCER; ARTICLE; ASTHMA; BEHAVIOR DISORDER; CHEST TIGHTNESS; CONJUNCTIVITIS; COST BENEFIT ANALYSIS; COUGHING; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FOOD AND DRUG ADMINISTRATION; HUMAN; IRRITABLE COLON; LIP DISEASE; META ANALYSIS (TOPIC); NONHUMAN; OROMUCOSAL PRURITUS; PATIENT COMPLIANCE; PHARYNX EDEMA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHINITIS; RHINOCONJUNCTIVITIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW (TOPIC); UNITED STATES; VIRAL PHARYNGITIS;

ALLERGENS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERSENSITIVITY; META-ANALYSIS AS TOPIC; SUBLINGUAL IMMUNOTHERAPY; TREATMENT OUTCOME; UNITED STATES;

EID: 84893411646     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2014.35.3708     Document Type: Article

References (61)

1. Scadding GK, and Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 16:483-491, 1986.
2. Noon L. Prophylactic inoculation against hay fever. Lancet 1:1572-1573, 1911.
3. Commercial and pipeline insight: Allergic rhinitis low unmet needs leave limited scope for innovation. London, U.K.: Datamonitor, October 2007.
4. Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma and Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 131:1288-1296.e3, 2013.
5. Cox L, and Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 103:451-459, 2009.
6. Tucker MH, and Tankersley MS. Perception and practice of sublingual immunotherapy among practicing allergists. Ann Allergy Asthma Immunol 101:419-425, 2008.
7. Sikora J, and Tankersley M. ACAAI Immunotherapy and Diagnostics Committee. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: A follow-up survey. Ann Allergy Asthma Immunol 110:194-197.e4, 2013.
8. Moingeon P. Update on immune mechanisms associated with sublingual immunotherapy: Practical implications for the clinician. J Allergy Clin Immunol Pract 1:228-241, 2013.
9. Bagnasco M, Altrinetti V, Pesce G, et al. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol 138:197-202, 2005.
10. Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 100:122-129, 1997.
11. Passalacqua G, Villa G, Altrinetti V, et al. Sublingual swallow or spit? Allergy 56:578, 2001.
12. Rienzo VD, Minelli M, Musarra A, et al. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 35:560-564, 2005.
13. Kildsgaard J, Brimnes J, Jacobi H, and Lund K. Sublingual immunotherapy in sensitized mice. Ann Allergy Asthma Immunol 98:366-372, 2007.
14. Abramson MJ, Puy RM, and Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 8:CD001186, 2010.
15. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007:CD001936, 2007.
16. Frew AJ, Powell RJ, Corrigan CJ, and Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117:319-325, 2007.
17. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118: 434-440, 2006.
18. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 120:1338-1345, 2007.
19. Khinchi MS, Poulsen LK, Carat F, et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: A randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59:45-53, 2004.
20. Yukselen A, Kendirli SG, Yilmaz M, et al. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: A randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 157:288-298, 2011.
21. Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergen-specific immunotherapy: Combination of sublingual and subcutaneous routes. J Allergy Clin Immunol 128:808-815.e7, 2011.
22. Varney VA, Gaga M, Frew AJ, et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 302:265-269, 1991.
23. Howarth P, Malling HJ, Molimard M, and Devillier P. Analysis of allergen immunotherapy studies shows increased clinical efficacy in highly symptomatic patients. Allergy 67:321-327, 2012.
24. Food and Drug Administration Center for Biologics Evaluation and Research Allergenic Products Advisory Committee. Capital Reporting Company. http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/ bloodvaccinesandotherbiologics/allergenicproductsadvisorycommittee/ucm254886. htm Allergenic Products Advisory Committee Meeting, May 12, 2011, Bethesda, MD.
25. Cox LS, Larenas Linnemann D, Nolte H, et al. Sublingual immunotherapy: A comprehensive review. J Allergy Clin Immunol 117:1021-1035, 2006.
26. Wahn U, Klimek L, Ploszczuk A, et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: A double-blind, placebo-controlled study. J Allergy Clin Immunol 130:886-893.e5, 2012.
27. Creticos P, Esch R, Couroux P, et al. A randomized, doubleblind, placebo-controlled, parallel trial of standardized short ragweed sublingual allergy immunotherapy liquid extract in adult subjects with ragweed-induced allergic rhinoconjunctivitis. J Allergy Clin Immuno 131:AB146, 2013.
28. Durham S, Yang W, Pedersen M, et al. Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117:802-809, 2006.
29. Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre-and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 128:559-566, 2011.
30. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: The ECRIT study. Allergy 64:1394-1401, 2009.
31. Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol 124:471-477.e1, 2009.
32. Malling H, Didier A, Horak F, et al. Post-treatment, long-term clinical efficacy of a 300 IR sublingual tablet of 5-grass pollen allergen extract in adults with grass pollen-induced allergic rhinoconjunctivitis. J Allergy Clin Immunol 129:AB144, 2012.
33. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 129:717-725.e5, 2012.
34. Marogna M, Bruno M, Massolo A, and Falagiani P. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: A long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol 142:70-78, 2007.
35. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study. J Allergy Clin Immunol 126:969-975, 2010.
36. Nelson HS, Oppenheimer J, Vatsia GA, and Buchmeier A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 92:229-236, 1993.
37. Esch RE, Bush RK, Peden D, and Lockey RF. Sublingual-oral administration of standardized allergenic extracts: Phase 1. safety and dosing results. Ann Allergy Asthma Immunol 100: 475-481, 2008.
38. Skoner D, Gentile D, Bush R, et al. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol 125:660-666, 666.e1-666.e4, 2010.
39. Nolte H, Hebert J, Berman G, et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol 110: 450-456.e4, 2013.
40. Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol 131:1342-1349.e6, 2013.
41. Nayak AS, Atiee GJ, Dige E, et al. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. Allergy Asthma Proc 33:404-410, 2012.
42. Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 127:64-71.e1-e4, 2011.
43. Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: The importance of allergen-specific serum IgE. J Allergy Clin Immunol 130: 1327-1334, 2012.
44. Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 127:72-80, 80.e1-e2, 2011.
45. Esch RE. Specific immunotherapy in the U.S.A.: General concept and recent initiatives. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 94:17-22, 2003.
46. Calderon MA, Cox L, Casale TB, et al. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: Looking at the published evidence. J Allergy Clin Immunol 129:929-934, 2012.
47. Amar SM, Harbeck RJ, Sills M, et al. Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 124:150-156.e1-e5, 2009.
48. Swamy RS, Reshamwala N, Hunter T, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol 130:215-222.e7, 2012.
49. Bush RK, Swenson C, Fahlberg B, et al. House dust mite sublingual immunotherapy: Results of a US trial. J Allergy Clin Immunol 127:974-981.e1-7, 2011.
50. Wood RA, Togias A, Wildfire J, et al. Development of cockroach immunotherapy by the Inner-City Asthma Consortium. J Allergy Clin Immunol DOI: 10.1016/j.jaci.2013.08.047 [Epub ahead of print].
51. CalderónMA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: Mode of action and its relationship with the safety profile. Allergy 67:302-311, 2012.
52. de Groot H, and Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 64:963-964, 2009.
53. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 64(suppl 91):1-59, 2009.
54. Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: Patterns of care, resource use, and costs. J Allergy Clin Immunol 121:227-232, 2008.
55. Senna G, Lombardi C, Canonica GW, and Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol 126:668-669, 2010.
56. Pajno GB, Caminiti L, Crisafulli G, et al. Adherence to sublingual immunotherapy in preschool children. Pediatr Allergy Immunol 23:688-689, 2012.
57. Vita D, Caminiti L, Ruggeri P, and Pajno GB. Sublingual immunotherapy: Adherence based on timing and monitoring control visits. Allergy 65:668-669, 2010.
58. Cox L, Esch RE, Corbett M, et al. Allergen immunotherapy practice in the United States: Guidelines, measures, and outcomes. Ann Allergy Asthma Immunol 107:289-299, 2011.
59. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 127: S1-S55, 2011.
60. Cortellini G, Spadolini I, Patella V, et al. Sublingual immunotherapy for Alternaria-induced allergic rhinitis: A randomized placebo-controlled trial. Ann Allergy Asthma Immunol 105: 382-386, 2010.
61. Valovirta E, Jacobsen L, Ljoørring C, et al. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 61:1177-1183, 2006.